CTIS2023-503723-26-00进行中(未招募)1 期
Cumulative exposure to Fludarabine in patients undergoing reduced intensity allogeneic stem cell transplantation in Belgium - RIC-F
niversitair Ziekenhuis Gent0 个研究点目标入组 50 人开始时间: 2024年4月2日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+(—)
- 性别
- All
入选标准
- •Age = 18 years, Be able to understand and sign an informed consent, Hematological malignancy, Women of childbearing potential (WOCBP), defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or is not postmenopausal, and men who are sexually active must use a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for participants participating in clinical trials. Men must use a highly effective method of birth control and agree not to father a child or donate sperm during and after the study. For females, these restrictions apply for 6 months after chemotherapy/conditioning. For males, these restrictions apply for 6 months after chemotherapy/conditioning, Allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning regimen containing IV Fludarabine 30 mg/m² for 5 days, IV Melphalan 100 or 140 mg/m² in total and IV ATG (Thymoglobulin or Grafalon according to local standard protocol), Use of Tacrolimus or Ciclosporin and Mycophenolate Mofetil (MMF) as graft versus host disease (GvHD) prevention, Human leukocyte antigen (HLA) identical sibling donor, 10/10 HLA matched unrelated donor or 9/10 mismatched unrelated donor
排除标准
- •Any condition not fulfilling inclusion criteria, Pregnancy or lactation, Known allergic reactions to components of the conditioning regimen (Fludarabine, Melphalan, ATG), No other line available for blood sampling than the infusion line through which Fludarabine was administered (patients with a double or triple lumen central catheter will not be excluded as a second lumen is available for sampling) and patient unable or unwilling to undergo peripheral blood sampling, Patients on dialysis, Renal insufficiency with creatinine clearance < 30 ml/min, Acute or chronic active infection, Decompensated hemolytic anemia
研究者
相似试验
招募中
Unknown
Investigation of fludarabine exposure in relation to individual renal function in patients with allogeneic hematopoietic stem cell transplantation and patients with CART cell therapyPatients with allogeneic stem cell transplantation or CART cell therapyDRKS00033126niversitätsklinikum Hamburg-Eppendorf50
进行中(未招募)
不适用
A phase II study in patients with fludarabine refractory CLL: Dasatinib treatment combination for Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL) - D’accord studyEUCTR2008-002236-15-NLAcademic Medical Center
招募中
Unknown
Investigations into the influence of fludarabine exposure on the outcomeof patients after CAR-T cell therapyC90C83Multiple myeloma and malignant plasma cell neoplasmsNon-follicular lymphomaDRKS00033974niversitätsklinikum Hamburg Eppendorf200
已完成
3 期
GOELAMS SA4 Study: the Role of Fludarabine in the Treatment of Acute Myeloid Leukemia in the ElderlyAcute Myeloid LeukemiaNCT00925873French Innovative Leukemia Organisation303
招募中
不适用
Individualized dosing of fludarabine during innate allo SCT: A randomized phase II studyHematological malignancies, Allogeneic stem cell transplantation, personalized dosing of fludarabineNL-OMON24753niversity Medical Center Utrecht (UMCU)98
